Charcot Neuroarthropathy: A Major Cause of Morbidity in Diabetes

Poll

What role do bisphosphonates play in the management of a Charcot joint? Is arthrodesis preferred to osteotomy? What's the most common complication of Charcot foot? Take this mini-quiz.

 

Charcot neuroarthropathy is a major cause of morbidity for patients with diabetes mellitus.

Which statement about this neuropathy is false?

A. Bisphosphonates may expedite conversion of an active Charcot foot to a more stable, chronic stage.
B. Bisphosphonates significantly minimize bone resorption in patients with Charcot foot.
C. For medial column or more severe deformities, arthrodesis procedures are preferred to osteotomies.
D. The most common complication of Charcot foot is infection secondary to plantar ulcerations.
Recent Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Optimizing Diabetes Therapies with New Classifications
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Should We Reclassify Diabetes Subtypes?
Related Content
Alie Rezaie, MD | Credit: Cedars-Sinai

Surge in New GLP-1 Prescriptions Driven by Semaglutide's Popularity, Study Shows

Patrick Campbell
July 22nd 2024
Article
John Buse, MD, PhD | Credit: UNC School of Medicine

Diabetes Dialogue: CATALYST Trial and Hypercortisolism in T2D, with John Buse, MD, PhD

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
July 15th 2024
Podcast
FDA Issues CRL to Once-Weekly Insulin Icodec | Image Credit: US Food and Drug Administration

FDA Issues Complete Response Letter for Once-Weekly Insulin Icodec

Connor Iapoce
July 11th 2024
Article
Diabetes Dialogue: ADA 2024 Diabetes Technology Recap

Diabetes Dialogue: ADA 2024 Diabetes Technology Recap

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES;Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
July 3rd 2024
Podcast
Brendon Neuen, MBBS, PhD | Credit: X.com

SGLT2 Inhibitor, GLP-1 RA Combination Improves Cardiovascular, Kidney Outcomes in Diabetes

Abigail Brooks, MA
July 9th 2024
Article
Nicholas Stucky, MD, PhD | Credit: LinkedIn

Tirzepatide Bests Semaglutide in Real-World Weight Loss Analysis

Patrick Campbell
July 8th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.